EU Industry Wants End To Isolated National Measures On Coronavirus
Unilateral Supply-Chain Policies Could Lead To Damaging ‘Tit For Tat’
A host of European pharmaceutical industry associations, including off-patent body Medicines for Europe, has urged EU trade ministers to push back against European and global restrictions on the movement of medicines and medical equipment that are hampering the international supply chain's response to the coronavirus pandemic.
You may also be interested in...
Medicines for Europe has responded to a European Commission announcement on the EU’s international trade strategy by setting out its priorities in this area for the pharmaceutical sector, including improved international collaboration on supply chain security as well as stronger co-operation in the field of intellectual property.
Medicines for Europe has renewed its call for a modern digital regulatory infrastructure in the wake of the COVID-19 pandemic to bolster communication and preparedness for future health crises, insisting that there is “no further excuse to delay.”
India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.